Hybio Pharmaceutical Co., Ltd. Stock: price and insider trades · China
翰宇药业
Hybio Pharmaceutical Co., Ltd.: what insiders have been doing
Hybio Pharmaceutical Co., Ltd. belongs to the Health Care sector. Filings by its managers are published through SSE / SZSE (CSRC). Nothing new has been filed by managers of Hybio Pharmaceutical Co., Ltd. in twelve months, the latest record being from 2 June 2023.
Our records for Hybio Pharmaceutical Co., Ltd. go back to 2023, with no purchases and 4 sales on the open market in total.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and Vetoquinol SA. This summary is built from SSE / SZSE (CSRC) disclosures alone and does not predict where the share price will go.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 43,200 shares7.5% of flowA股XSHESZSE:173000006637092400
- 645,100 shares100.0% of flowA股XSHESZSE:173000006637092450
- 1,950,000 shares100.0% of flowA股XSHESZSE:173000006614165920
- 550,000 shares92.5% of flowA股XSHESZSE:173000006546648640
4 of 4 declarations
About Hybio Pharmaceutical Co., Ltd.
翰宇药业 is a company in the health and pharmaceutical sector, listed on the XSHE market. It focuses on the development and production of innovative medicines.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
